Remodulin Pump Systems

At United Therapeutics, we are committed to transforming patient expectations for life with pump therapy. We strive to bring innovation to PAH treatment that goes beyond delivering therapeutic excellence, including an ongoing investment in state-of-the-art delivery systems.

Training on each pump is available through Specialty Pharmacies, SP nurses, and United Therapeutics Representatives.

Pump system options are available

There are different types of pump systems for administration of Remodulin: subcutaneous (SC) and intravenous (IV).

Sign up for updates about new pumps.

Explore more information about the SC Remodulin pump options from United Therapeutics

Traditional, all-in-one SC Remodulin pump

CADD-MS® 3

The all-in-one pump

Learn More
Small, discreet pump helping to simplify delivery of Remodulin

Coming soon—Remunity

The small, simple, and safe SC prefilled pump that is water resistant and provides state-of-the-art dosing accuracy

Learn More

Learn more about the IV Remodulin pump option

Proven pump for continuous IV delivery of Remodulin and other medicines

CADD-Legacy® 1

Reliably delivering Remodulin since 2004

Learn More

IN DEVELOPMENT*: The Implantable System for Remodulin (ISR)

Implantable System for Remodulin (ISR)

In development—Implantable System for Remodulin (ISR)

Learn More

*FDA requires that certain conditions of Medtronic’s PMA approval of the Implantable System for Remodulin must be satisfied prior to launch or sale of the Implantable System for Remodulin; accordingly, Implantable System for Remodulin labeling may be revised in the process of satisfying such conditions for approval.

PAH=pulmonary arterial hypertension; PMA=premarket approval; SP=Specialty Pharmacy.

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Adverse Reactions

Drug Interactions

Specific Populations

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).